Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Primary myelofibrosis characterized by bone marrow hypercellularity and the presence of atypical megakaryocytes. There is no increase in the percentage of myeloblasts and no significant increase in reticulin or collagen fibrosis in the bone marrow.
Biomarker and diagnostic research for cellular phase chronic idiopathic myelofibrosis has been reported in the published literature.
2 clinical trials registered, 1 recruiting. Interventions under study include drug therapy. Pipeline includes 1 PHASE3, 1 PHASE1. Research is primarily sponsored by academic and government institutions.
38 publications have been identified in PubMed for cellular phase chronic idiopathic myelofibrosis. Research spans Clinical Trial Publication (42%), Review / Meta-Analysis (16%), and Epidemiology / Natural History (16%).
Research Type | Count | % of Total |
|---|---|---|
Clinical study results | 16 |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 6:51 AM UTC
Research summaries | 6 | 16% |
Disease patterns and progression | 6 | 16% |
Laboratory research | 4 | 11% |
Testing and diagnosis research | 3 | 8% |
New treatment approaches | 2 | 5% |
Patient case studies | 1 | 3% |
Vachhani P (2026). [PMID: 41793151](https://pubmed.ncbi.nlm.nih.gov/41793151/). *Future oncology (London, England)*. [Diagnostic / Biomarker]
Passamonti F (2026). [PMID: 41846295](https://pubmed.ncbi.nlm.nih.gov/41846295/). *Hematol Oncol*. [Clinical Trial Publication]
Cavalca F (2026). [PMID: 41537951](https://pubmed.ncbi.nlm.nih.gov/41537951/). *Annals of hematology*. [Epidemiology / Natural History]
Boldrini V (2026). [PMID: 41665690](https://pubmed.ncbi.nlm.nih.gov/41665690/). *Current hematologic malignancy reports*. [Clinical Trial Publication]
Shahzad M (2026). [PMID: 40930937](https://pubmed.ncbi.nlm.nih.gov/40930937/). *Clinical lymphoma, myeloma & leukemia*. [Clinical Trial Publication]
Palandri F (2026). [PMID: 42118670](https://pubmed.ncbi.nlm.nih.gov/42118670/). *Cancer*. [Epidemiology / Natural History]
Harrison CN (2026). [PMID: 41890273](https://pubmed.ncbi.nlm.nih.gov/41890273/). *Ther Adv Hematol*. [Clinical Trial Publication]
Kuruoğlu T (2026). [PMID: 42043354](https://pubmed.ncbi.nlm.nih.gov/42043354/). *Mikrobiyol Bul*. [Case Report / Case Series]
Thiele J (2025). [PMID: 40038244](https://pubmed.ncbi.nlm.nih.gov/40038244/). *Blood cancer journal*. [Diagnostic / Biomarker]
Varricchio L (2025). [PMID: 40643151](https://pubmed.ncbi.nlm.nih.gov/40643151/). *Blood*. [Basic Science / Preclinical]